Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. Innoviva’s other innovative healthcare assets include infectious disease and ...

GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

Tariffs inject significant uncertainty in 2025, but crude oil prices may have bottomed. We sell different types of products and services to both investment professionals and individual investors ...

Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta. Results from GSK's combination have underwhelmed until now, and failed to show superiority to the older ...

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as ...

To ensure enough medications get into your lungs, an add-on device called a spacer can be connected to the mouthpiece ... Examples of DPIs include those with the names Digihaler, Handihaler, Ellipta, ...